1779 — LongBio Pharma (Suzhou) Share News
0.000.00%
Last trade - 00:00- HK$4.53bn
- HK$3.52bn
Brief: Longbio Pharma (Suzhou) Says NMPA Accepts BLA For Lp-003 For Seasonal Allergic Rhinitis
Brief: Longbio Pharma (Suzhou) Says FDA Approves Clinical Trial Application For LP-3 For Peanut Allergy
Brief: Longbio Pharma (Suzhou)Says Phase III Trial Of LP-3 For Seasonal Allergic Rhinitis Meets Primary Endpoints
LongBio Pharma shines in Hong Kong debut; Lung Fung, Dajin fall